ABSTRACT
The proportion of adults aged 60 years and over is expected to increase over the coming decades. This ageing of the population represents an important health issue, given that marked reductions to cerebral macro- and microstructural integrity are apparent with increasing age. Reduced cerebral structural integrity in older adults appears to predict poorer cognitive performance, even in the absence of clinical disorders such as dementia. As such, it is becoming increasingly important to identify those factors predicting cerebral structural integrity, especially factors that are modifiable. One such factor is nutritional intake. While the literature is limited, data from available cross-sectional studies indicate that increased intake of nutrients such as B vitamins (for example, B6, B12 and folate), choline, n-3 fatty acids and vitamin D, or increased adherence to prudent whole diets (for example, the Mediterranean diet) predicts greater cerebral structural integrity in older adults. There is even greater scarcity of randomised clinical trials investigating the effects of nutritional supplementation on cerebral structure, though it appears that supplementation with B vitamins (B6, B12 and folic acid) or n-3 fatty acids (DHA or EPA) may be beneficial. The current review presents an overview of available research examining the relationship between key nutrients or adherence to select diets and cerebral structural integrity in dementia-free older adults.
Subject(s)
Aging , Brain/drug effects , Cognition/drug effects , Cognitive Dysfunction/prevention & control , Diet , Dietary Supplements , Aged , Aged, 80 and over , Choline/pharmacology , Choline/therapeutic use , Dementia/prevention & control , Fatty Acids, Omega-3/pharmacology , Fatty Acids, Omega-3/therapeutic use , Humans , Middle Aged , Polyphenols/pharmacology , Polyphenols/therapeutic use , Vitamins/pharmacology , Vitamins/therapeutic useABSTRACT
Previous research has suggested that multivitamin (MV) supplementation may be associated with beneficial effects for mood and general well-being, although treatment durations have typically been less than 90 days, samples have often been restricted to males only and acute effects have not been adequately differentiated from chronic effects. In the current study a MV supplement containing high levels of B-vitamins was administered daily to 138 healthy young adult participants between the ages of 20 and 50 years over a 16-week period. Chronic mood measures (GHQ-28, POMS, Chalder fatigue, PILL, Bond-Lader and custom visual analogue scales) were administered pre-dose at baseline, 8- and 16-weeks. Changes in Bond-Lader and VAS in response to a multi-tasking framework (MTF) were also assessed at 8- and 16-weeks. For a subset of participants, at-home mobile-phone assessments of mood were assessed on a weekly basis using Bond-Lader and VAS. No significant treatment effects were found for any chronic laboratory mood measures. In response to the MTF, a significant treatment x time interaction was found for STAI-S, with a trend towards a greater increase in stress ratings for male participants in the MV group at 16 weeks. However, this finding may have been attributable to a larger proportion of students in the male MV group. In contrast, at-home mobile-phone assessments, where assessments were conducted post-dose, revealed significantly reduced stress, physical fatigue and anxiety in the MV group in comparison to placebo across a number of time points. Further research using both acute and chronic dosing regimens are required in order to properly differentiate these effects.
Subject(s)
Affect/drug effects , Dietary Supplements , Health Status , Vitamins/administration & dosage , Adult , Anxiety/prevention & control , Cell Phone , Double-Blind Method , Fatigue/prevention & control , Female , Humans , Male , Middle Aged , Placebos , Stress, Psychological/prevention & control , Surveys and Questionnaires , Young AdultSubject(s)
Dentifrices/therapeutic use , Silicon Dioxide/therapeutic use , Tooth Bleaching/methods , Tooth Discoloration/therapy , Adsorption , Chemistry, Pharmaceutical , Color , Dentifrices/chemistry , Esthetics, Dental , Humans , Oxidants/chemistry , Oxidants/therapeutic use , Porosity , Silicon Dioxide/chemistry , Surface Properties , Surface-Active Agents/chemistry , Surface-Active Agents/therapeutic use , Technology, Pharmaceutical , Tooth/anatomy & histology , Tooth Discoloration/prevention & control , Toothbrushing , Toothpastes/chemistry , Toothpastes/therapeutic use , Water/chemistryABSTRACT
These laboratory studies examined the stain removal efficacy and hard tissue abrasivity of a new dentifrice formulation--Crest Extra Whitening--based on the incorporation of elevated concentrations of a proprietary silica. Cleaning power assessments were made using a modification of the laboratory test method developed by Stookey and associates at Indiana University Oral Health Research Institute. Abrasion assessments were made using Radioactive Enamel and Radioactive Dentin Abrasivity (REA and RDA) measures. Results show that Crest Extra Whitening dentifrice produced statistically significantly improved stain removal when compared to a number of conventional dentifrices, including Crest Cavity Protection and Crest Tartar Protection, and a number of recently marketed cleaning and whitening dentifrices. Laboratory studies further demonstrated that the Crest Extra Whitening dentifrice produces dentin and enamel abrasivity similar to conventional silica dentifrices.
Subject(s)
Dental Enamel/ultrastructure , Dentifrices/therapeutic use , Dentin/ultrastructure , Silicon Dioxide/therapeutic use , Tooth Discoloration/therapy , Aluminum Oxide/therapeutic use , Animals , Bicarbonates/therapeutic use , Cariostatic Agents/therapeutic use , Cattle , Chemistry, Pharmaceutical , Color , Dental Calculus/therapy , Dental Deposits/therapy , Dentifrices/chemistry , Diphosphates/therapeutic use , Phosphorus Radioisotopes , Radiopharmaceuticals , Silicon Dioxide/chemistry , Sodium Fluoride/therapeutic use , Surface Properties , Technology, Pharmaceutical , Tooth Bleaching , Toothbrushing/instrumentationABSTRACT
A nine-week, double blind clinical trial was conducted to evaluate the effectiveness of a novel tartar control whitening dentifrice with a silica-based abrasive system on induced dental stain. The study model involved three weeks of stain induction followed by six weeks of unsupervised brushing to assess efficacy. To induce stain, 222 healthy adult volunteers received a dental prophylaxis, and then began a limited brushing regimen supplemented by three-times daily rinsing with tea and once daily rinsing with 15 ml of 0.12% chlorhexidine. This regimen was suspended, and 187 subjects with tooth stain were entered into a six-week clinical trial where they were randomized to either a silica-based tartar control whitening dentifrice or a marketed regular dentifrice control, balancing for stain levels and smoking status. At baseline, three and six weeks, stain area and stain intensity were measured on the 8 anterior teeth using the Lobene Index. After six weeks' use, composite Lobene means were 35% lower for the whitening dentifrice compared to the regular control. In addition to the overall reductions, there were statistically significant reductions in stain area (p < 0.015) and stain intensity (p < 0.01) at both three and six weeks. The tartar control whitening dentifrice was effective in removing stain on the gingival margins and elsewhere on the body of the tooth. Safety profiles for the two test dentifrices were generally similar. After three and six weeks' use, the tartar control whitening dentifrice reduced chlorhexidine and tea stain compared to the marketed control.
Subject(s)
Dental Calculus/prevention & control , Dentifrices/therapeutic use , Tooth Bleaching , Tooth Discoloration/therapy , Adult , Analysis of Variance , Anti-Infective Agents, Local/adverse effects , Cariostatic Agents/chemistry , Cariostatic Agents/therapeutic use , Chlorhexidine/adverse effects , Dentifrices/chemistry , Diphosphates/chemistry , Diphosphates/therapeutic use , Double-Blind Method , Female , Follow-Up Studies , Gingiva/pathology , Humans , Male , Safety , Silicon Dioxide/chemistry , Silicon Dioxide/therapeutic use , Smoking/adverse effects , Sodium Fluoride/chemistry , Sodium Fluoride/therapeutic use , Tea/adverse effects , Tooth/pathology , Tooth Discoloration/chemically induced , Tooth Discoloration/pathology , ToothbrushingABSTRACT
BACKGROUND: This study examined the effects of antioxidant vitamins A, C, and E on nuclear transcription factor-kappa B (NF-kappaB) nuclear translocation, on secretion of inflammatory cytokines by cardiac myocytes, and on cardiac function after major burn trauma. METHODS: Adult rats were divided into four experimental groups: group I, shams; group II, shams given oral antioxidant vitamins (vitamin C, 38 mg/kg; vitamin E, 27 U/kg; vitamin A, 41 U/kg 24 hours before and immediately after burn); group III, burns (third-degree scald burn over 40% total body surface area) given lactated Ringer's solution (4 mL/kg/% burn); and group IV, burns given lactated Ringer's solution plus vitamins as described above. Hearts were collected 4, 8, 12, and 24 hours after burn to assay for NF-kappaB nuclear translocation, and hearts collected 24 hours after burn were examined for cardiac contractile function or tumor necrosis factor-alpha secretion by cardiomyocytes. RESULTS: Compared with shams, left ventricular pressure was lower in burns given lactated Ringer's solution (group III) (88 +/- 3 vs. 64 +/- 5 mm Hg, p < 0.01) as was +dP/dt max (2,190 +/- 30 vs. 1,321 +/- 122 mm Hg/s) and -dP/dt max (1,775 +/- 71 vs. 999 +/- 96 mm Hg, p < 0.01). Burn injury in the absence of vitamin therapy (group III) produced cardiac NF-kappaB nuclear migration 4 hours after burn and cardiomyocyte secretion of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 by 24 hours after burn. Antioxidant therapy in burns (group IV) improved cardiac function, producing left ventricular pressure and +/-dP/dt (82 +/- 2 mm Hg, 1,880 +/- 44 mm Hg, and 1,570 +/- 46 mm Hg/s) comparable to those measured in shams. Antioxidant vitamins in burns inhibited NF-kappaB nuclear migration at all times after burn and reduced burn-mediated cytokine secretion by cardiomyocytes. CONCLUSION: These data suggest that antioxidant vitamin therapy in burn trauma provides cardioprotection, at least in part, by inhibiting translocation of the transcription factor NF-kappaB and interrupting cardiac inflammatory cytokine secretion.
Subject(s)
Antioxidants/therapeutic use , Ascorbic Acid/therapeutic use , Burns/complications , Burns/immunology , Interleukin-1/metabolism , Interleukin-6/metabolism , Myocardial Contraction/drug effects , Myocardial Contraction/immunology , Myocardium/immunology , Myocardium/metabolism , NF-kappa B/drug effects , NF-kappa B/immunology , Oxidative Stress/immunology , Protein Transport/drug effects , Protein Transport/immunology , Tumor Necrosis Factor-alpha/metabolism , Vitamin A/therapeutic use , Vitamin E/therapeutic use , Animals , Antioxidants/pharmacology , Ascorbic Acid/pharmacology , Body Surface Area , Burns/classification , Burns/physiopathology , Disease Models, Animal , Drug Evaluation, Preclinical , Hemodynamics/drug effects , Hemodynamics/immunology , Inflammation , Injury Severity Score , Myocardium/cytology , Rats , Rats, Sprague-Dawley , Time Factors , Vitamin A/pharmacology , Vitamin E/pharmacologyABSTRACT
AIMS: Vascular endothelial dysfunction, an early marker of atherosclerosis, has been demonstrated in Type 2 diabetes mellitus (DM). Vitamin E preserves endothelial function in animal models of diabetes and reduces cardiovascular risk. We examined endothelial function and the effect of vitamin E supplements in uncomplicated Type 2 DM. METHODS: Forty-eight subjects with Type 2 DM and 21 controls had endothelial function assessed using forearm venous occlusion plethysmography with endothelium-independent (sodium nitroprusside) and dependent (acetylcholine, bradykinin) vasodilators. Those with diabetes received 1600 i.u. daily oral alpha-tocopherol or placebo, double-blind for 8 weeks, and had endothelial function reassessed. RESULTS: The diabetic group had higher HbA1c (6.9+/-1.4 vs 4.8+/-0.6%; P<0.01) and systolic (145+/-15 vs. 130+/-16 mm Hg; P<0.01) but not diastolic blood pressure (79+/-8 vs. 76+/-9 mm Hg; P = 0.15). There was blunted vasodilation to acetylcholine (15 microg/min; P<0.01) in subjects with diabetes. Vasodilation to sodium nitroprusside and bradykinin was similar (all P>0.1). Alpha-tocopherol did not affect vasodilation to nitroprusside (P>0.1), acetylcholine (P>0.1) or bradykinin (P>0.1). CONCLUSIONS: There may be receptor-specific endothelial dysfunction in subjects with uncomplicated Type 2 DM. This is not improved by treatment with alpha-tocopherol.
Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Dietary Supplements , Endothelium, Vascular/physiopathology , Vitamin E/therapeutic use , Administration, Oral , Case-Control Studies , Diabetes Mellitus, Type 2/physiopathology , Double-Blind Method , Female , Forearm/blood supply , Humans , Male , Middle Aged , Regional Blood Flow/drug effectsABSTRACT
OBJECTIVE: To compare the effectiveness and cost of self treatment of penile warts with a commercial preparation of podophyllotoxin 0.5% (PDX 0.5%) with podophyllin 0.5% and podophyllin 2.0% sourced from Podophyllum emodii. DESIGN: A prospective double blind randomised study. SUBJECTS: 315 patients with penile warts attending two departments of genitourinary medicine. MAIN OUTCOME MEASURES: Absence of warts, cessation of treatment due to severe side effects at 5 weeks. RESULTS: Of the 315 patients, 244 conformed to the protocol. Analysis was on an intention to treat basis. At 5 weeks no significant differences were found in the extent of healing of warts or in side effects for the three treatment groups. The costs of drug treatment (excluding staff time) are at least pounds 10.00 less for podophyllin than podophyllotoxin. A fourfold variation in the active constituents of the podophyllin preparations did not produce appreciably different clinical responses. In a subanalysis no evidence of deterioration in effectiveness of podophyllin over time was demonstrated. CONCLUSIONS: Penile warts in selected cases can be safely treated with 0.5-2.0% podophyllin self applied by the patient at a fraction of the cost of commercially available podophyllotoxin. The shelf life of the podophyllin extracts is at least 3 months. These findings may be especially relevant in countries where resources for health care are limited.
Subject(s)
Condylomata Acuminata/drug therapy , Keratolytic Agents/administration & dosage , Penile Diseases/drug therapy , Podophyllin/administration & dosage , Double-Blind Method , Drug Stability , Humans , Keratolytic Agents/adverse effects , Male , Penile Diseases/virology , Podophyllin/adverse effects , Podophyllotoxin/administration & dosage , Podophyllotoxin/adverse effects , Prospective Studies , Self AdministrationABSTRACT
This double-blind parallel-design clinical study compared the efficacy of a stabilized stannous fluoride dentifrice (Crest Plus Gum Care), baking soda and peroxide (NaF) dentifrice (Mentadent), and essential oil mouthrinse (Listerine) to a conventional NaF dentifrice (Crest) for the control of plaque, gingivitis and gingival bleeding over six months. Following an initial baseline examination and stratification, subjects received a complete oral prophylaxis and were distributed assigned test products. Following three and six months, subjects re-visited the clinic for examinations. Evaluations at baseline and at 3 and 6 months included soft tissue status. Löe-Silness gingivitis/gingival bleeding, Silness-Löe plaque and dental stain. Results subsequent to six months of product use were as follows: At six months, the stabilized stannous fluoride dentifrice was observed to produce statistically significant 17.5% reductions in gingivitis and 27.5% reductions in gingival bleeding relative to the NaF dentifrice. The combination of sodium fluoride dentifrice and essential oil mouthrinse produced statistically significant reductions of 7.4% in gingivitis and 10.8% in plaque as compared with the NaF dentifrice. The stabilized stannous fluoride dentifrice produced statistically significant reductions in both gingivitis (10.8%) and gingival bleeding (23.0%) relative to the combination of sodium fluoride dentifrice and essential oil mouthrinse. The baking soda and peroxide (NaF) dentifrice did not provide reductions in gingivitis, plaque or gingival bleeding as compared with the conventional NaF dentifrice. The stabilized stannous fluoride dentifrice provided statistically significant reductions in gingivitis as compared with the baking soda and peroxide dentifrice following six months of use, and both the essential oil mouthrinse and stabilized stannous fluoride dentifrice provided statistically significant reductions in gingivitis as compared with the baking soda and peroxide dentifrice following three months of use. These results support: 1) the efficacy of stabilized stannous fluoride dentifrice and the combination of sodium fluoride dentifrice and essential oil mouthrinse for the prevention of gingivitis; 2) the superior activity of stabilized stannous fluoride dentifrice as compared with a combination of sodium fluoride dentifrice and essential oil mouthrinse for the control of gingivitis and gingival bleeding; and 3) the lack of efficacy for baking soda and peroxide dentifrice for the control of plaque, gingivitis and gingival bleeding as compared with conventional fluoridated dentifrice.
Subject(s)
Dentifrices/therapeutic use , Gingivitis/prevention & control , Mouthwashes/therapeutic use , Adult , Analysis of Variance , Dental Plaque/prevention & control , Dental Plaque Index , Dentifrices/chemistry , Double-Blind Method , Drug Combinations , Female , Humans , Hydrogen Peroxide/therapeutic use , Male , Mouthwashes/chemistry , Periodontal Index , Salicylates/therapeutic use , Sodium Bicarbonate/therapeutic use , Sodium Fluoride/therapeutic use , Terpenes/therapeutic use , Tin Fluorides/therapeutic use , Treatment OutcomeABSTRACT
A new method, the Plaque Glycolysis and Regrowth Method (PGRM), is described for the evaluation of antimicrobial effects on plaque metabolism in vivo. The method relies on the experimental observation that in vivo sampled dental plaques, collected from different quadrants of the dentition, produce equivalent rates of metabolic activity and regrowth when similarly dispersed and normalized into incubation media. In applications of the technique to antimicrobial evaluations, overnight fasted dental plaque is collected from a non-treated quadrant of the dentition along the gingival margin. Topical formulations are used in vivo. Following this, dental plaques are collected from other dentition quadrants at extended times, allowing for the back diffusion, clearance and natural intraoral deactivation of antimicrobials within the oral cavity. In vivo treated and non-treated plaque samples are subsequently tested for metabolic and regrowth activity under controlled and standardized conditions in vitro following normalization for biomass. The technique thus combines the necessary biological factors important to the legitimate evaluation of antimicrobial effects in vivo, while benefiting from the improved precision and control provided by in vitro assessment of plaque activity. In this paper evidence is presented validating the PGRM method, and initial activity screens of commercial antimicrobial mouthrinses and toothpastes, including a new stabilized stannous fluoride dentifrice, are described.
Subject(s)
Dental Plaque/microbiology , Dental Plaque/prevention & control , Dentifrices/therapeutic use , Microbial Sensitivity Tests/methods , Mouthwashes/pharmacology , Analysis of Variance , Anti-Infective Agents, Local/pharmacology , Anti-Infective Agents, Local/therapeutic use , Biofilms/drug effects , Biofilms/growth & development , Cetylpyridinium/pharmacology , Cetylpyridinium/therapeutic use , Chlorhexidine/analogs & derivatives , Chlorhexidine/pharmacology , Chlorhexidine/therapeutic use , Cross-Over Studies , Dental Plaque/metabolism , Dentifrices/pharmacology , Drug Combinations , Fluorides, Topical/pharmacology , Fluorides, Topical/therapeutic use , Glycolysis/drug effects , Humans , Hydrogen-Ion Concentration , Mouthwashes/therapeutic use , Pilot Projects , Quaternary Ammonium Compounds/pharmacology , Quaternary Ammonium Compounds/therapeutic use , Reproducibility of Results , Salicylates/pharmacology , Salicylates/therapeutic use , Sodium Fluoride/pharmacology , Sodium Fluoride/therapeutic use , Terpenes/pharmacology , Terpenes/therapeutic use , Tin Fluorides/pharmacology , Tin Fluorides/therapeutic useABSTRACT
CASE REPORT--SUBJECTS--Three cases are described of long-standing vaginal candidosis due to Candida glabrata. These had failed to respond to local and systemic antifungals. In each case the infecting strain appeared resistant to a range of azole drugs in vitro. CLINICAL COURSE--Case one--This patient recovered following prolonged treatment with oral itraconazole in combination with oral and vaginal nystatin. Case two. Yeasts were eradicated from this patient following cyclical treatment with oral dydrogesterone; prolonged vaginal treatment with nystatin may have helped. Case three. This patient did not respond to a prolonged course of oral itraconazole in combination with vaginal and oral nystatin, oral medroxyprogesterone or intravaginal boric acid. Eradication of C glabrata was finally achieved by local application of 1% gentian violet. Shortly after eradication of the C glabrata infection, both Case two and Case three developed infections with other Candida species responsive to azole antifungals.
Subject(s)
Antifungal Agents/therapeutic use , Candidiasis, Vulvovaginal/drug therapy , Administration, Oral , Administration, Topical , Adult , Drug Resistance, Microbial , Econazole/therapeutic use , Female , Fluconazole/therapeutic use , Gentian Violet/therapeutic use , Humans , Itraconazole , Ketoconazole/analogs & derivatives , Ketoconazole/therapeutic use , Medroxyprogesterone Acetate/therapeutic use , Microbial Sensitivity Tests , Nystatin/therapeutic useABSTRACT
Historically, there has been considerable debate concerning the roles of loosely bound (calcium fluoride) and firmly bound (fluorapatite) fluoride for caries prevention. Research now shows that fluorapatite (FAP) is a finite reaction product of enamel/apatite fluoridation with or without CaF2 formation, suggesting that CaF2 always be considered as a supplement to, rather than a substitute for, FAP formation. In the presence of low levels of fluoride in the solution phase, the crystallization of hydroxyapatite is enhanced, while the corresponding dissolution is retarded. Fluoride in the bulk FAP or CaF2 solid phase, in contrast, has limited impact on crystal growth or dissolution kinetics. Both FAP and CaF2 can provide F to the solution phase to enhance remineralization and retard demineralization of enamel HAP crystallites. The FAP provides most of this F under low pH conditions, while CaF2 provides F at neutral or lower pH. The reactivity of fluoride on sound and carious enamel differs significantly. Carious enamel acquires more fluoride, acquires it more quickly, and itself acts as a source of retained fluoride in comparison with the more limited reactivity of sound enamel. Overall, the most important question concerning fluoride reactivity relates to its efficiency in enhancing remineralization or retarding demineralization processes. This is influenced not only by the reaction products, e.g., loosely or firmly bound fluoride, but also by the nature of the enamel substrate and frequency of application of the topical fluoridating agent. Inasmuch as the reactivity of bulk HAP is dominated by surface layers of FAP material, the debate over usefulness of various fluoride reaction products solely on a chemical level is no longer critical. Instead, all factors influencing the efficiency of a fluoridating regimen must be considered in the development of improved systems for caries prevention.
Subject(s)
Dental Caries/prevention & control , Fluorides/metabolism , Apatites/metabolism , Chemical Phenomena , Chemistry , Dental Caries/metabolism , Dental Enamel/metabolism , Fluorides/therapeutic use , HumansABSTRACT
The ability of experimental canine distemper infection to mobilize body lead deposits has been studied in Beagle dogs previously subacutely intoxicated with lead carbonate. For comparative purposes dogs were included which had either received lead only or distemper only or remained undosed. It was found that in dogs predosed with lead, distemper infection resulted in a significant increase in lead levels in blood and urine; this coincided with the peak body temperatures reached on the third day post infection. It was also found that the lead content of the liver and bone of these dogs was considerably higher than that of dogs receiving lead alone; at the same time bone phosphorus showed a marked decrease while bone calcium values remained similar to undosed controls.